Prescriber's Corner

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia

Alison Steinbach, PharmD, Stephen M. Clark, PharmD, and Amber B. Clemmons, PharmD, BCOP

From Georgia Regents Medical Center and University of Georgia College of Pharmacy, Augusta, Georgia

Correspondence to: Alison Steinbach, PharmD, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212. E-mail: asteinba@wpahs.org


J Adv Pract Oncol 2013;4:451–455 | DOI: 10.6004/jadpro.2013.4.6.8 | © 2013 Harborside Press®


  

ABSTRACT

Bosutinib (Bosulif), a new second-generation tyrosine kinase inhibitor targeting the Bcr-Abl protein, was recently approved by the FDA for the treatment of select CML patients with resistance or intolerance to prior therapy. Read about the key trials, dosing and administration, and side effects of this important agent.


For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me